Ethambutol and tuberculosis, a neglected and confused chiral puzzle

Chemical Analysis

Volumn 142, Issue , 1997, Pages 235-261

  Blessington, Bernard ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347171891     PISSN: 00692883     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (143)

1. Ryan, F. (1992). Tuberculosis: The Greatest Story Never Told. Bromsgrove. England: Swift Publishers.
2. Bunyan, J. (1680). The Life and Death of Mr. Badman.
3. TB. a Global Emergency (1993). World Health, No. 4 (July-Aug).
4. Dubos, R. and Dubos, J. (1952). The White Plague. New Brunswitch, N.J.: Rutgers Univ. Press.
5. Wilkinson, R. G., Shepherd, R. G., Thomas, J. P., and Baughn, C. (1961). Stereospecificity in a new type of synthetic antituberculous agent. J. Am. Chem. Soc., 83, 2212.
6. Thomas, J. P., Baughn, R. G., Wilkinson, R. G., and Shepherd R. G. (1961). A new synthetic compound with antituberculous activity in mice: Ethambutol. Am . Rev. Resp. Dis., 83, 891.
7. Shepherd, R. G. and Wilkinson, R. G. (1962). Antituberculous agents, II. N,N′-diisopropylethylenediamine and analogs. J. Med. Pharm. Chem., 5, 823.
8. Wilkinson, R. G., Cantrall, M. B., and Shepherd, R. G. (1962). Antituberculous agents III. (+)-2,2′-(Ethylenediimino)-di-1-butanol and some analogs. J. Med. Pharm. Chem., 5, 835.
9. Shepherd, R. G., Baughn, C., Cantrall, M. L., Goodstein, B., Thomas, J. P., and Wilkinson, R. G. (1966). Antituberculous agents IV. Ann. New York Acad. Sci. 135, 686-710.
10. Cantrall, M. B., Wilkinson, R. G., and Shepherd, R. G. (1966). Antituberculous agents V. Hydroxy and ether analogs of ethambutol. Selective O-alkylation of aminoalcohols. J. Med. Chem., 9.
11. Cantrall, M. B., Wilkinson, R.G., and Shepherd, R. G. (1966). Antituberculous agents VI. Varied branching of the alkyl group in the antimycobacterial N,N′-dialkylethylenediamines. J. Med. Chem., 9.
12. Goodstein, B. B. and Shepherd, R. G. (1966). Antituberculous agents VII. Modifications of the alkylene chain and of the basic centres of the antimycobacterial ethylenediamines. J. Med. Chem., 9.
13. Cantrall, M. B., Wilkinson, R.G., and Shepherd, R. G. (1966). Antituberculous agents VIII. Alkyl-substituted N.N′-di-sec-butyl ethylenediamines. J. Med. Chem., 9.
14. Cantrall, M. B., Wilkinson, R.G., Shepherd, R. G., Goodstein, B. B., and Sassiver, M. L. (1966). Antituberculous agents IX. Neighboring group effects in synthesis of ethylenediamines. J. Med. Chem., 9.
15. Cantrall, M. B., Wilkinson, R.G., and Shepherd, R. G. (1966). Antituberculous Agents X. Stereospecificity In N,N′-di-sec-butyl ethylenediamines. Absolute configuration of ethambutol. J. Med. Chem., 9.
16. Ringler, I. (1977). Splitting the antipodes. In F. H. Clarke (ed.), How Modern Medicines are Discovered, New York: Futura Pub. Co.
17. British Pharmacopoeia, Vol. I (1980). London: HMSO.
18. U.S. Pharmacopoeia, revision XXI (1995). Rockville, MD: USP Convention.
19. European Pharmacopoeia, 2nd ed. (1987). 553, Maisonneuve SA. St. Ruffine.
20. British Pharmacopoeia, Vol. I (1993). London: HMSO.
21. Lee, C. S., and Benet, L. Z. (1978). Ethambutol. In K. Florey (ed.), Analytical Profiles of Drug Substances, Vol. 7. New York: Academic Press, pp. 231-249.
22. Beggs, W. H. (1979). Ethambutol. In F. F. Hahn (ed.), Antibiotics, V, New York: Springer-Verlag, pp 43-46.
23. Smith, J. L. (1987). Should ethambutol be barred. J. Clini. Neuro-Ophthalmol., 7, 84-86.
24. Alvarez, K. L. and Krop, L. C. (1993). Ethambutol-induced ocular toxicity revisited. Annals Pharmacother., 27, 102-103.
25. Schild, H. S. and Fox, B. C. (1991). Rapid-onset reversible ocular toxicity from ethambutol therapy. Am. J. Med., 90, 404-406.
26. Kumar, A., Sandramoul, S., Verma, L., Tewari, H. K., and Khosla, P. K. (1993). Ocular ethambutol toxicity - is it reversible. J. Clin. Neuro-Ophthalmol., 13, 15-17.
27. Polak, B. C. P., Leys, M., and Yanlith, G. H. M. (1985). Blue-yellow color-vision changes as early symptoms of ethambutol oculotoxicity. Ophthalmologica, 191, 223-226.
28. Fledelius, H. C., Petrera, J. E., Skjodt, K., and Trojaborg, W. (1987). Ocular ethambutol toxicity - a case-report with electrophysiological considerations and a review of Danish cases 1972-81. Acta Ophthalmologica, 65, 251-255.
29. Harcombe, A., Kinnear, W., Britton, J., and Macfarlane, J. (1991). Ocular toxicity of ethambutol. Resp. Med., 85, 151-153.
30. Kahana, L. M. (1987). Toxic ocular effects of ethambutol. Can Med. Assoc. J., 137, 213-216.
31. Zimmer, B. L., Deyoung, D. R., and Roberts, G. D. (1982). Invitro synergistic activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against mycobacterium-avium-intracellulare complex. Antimicrob. Agents Chemother., 22, 148-150.
32. Heifets, L. B., (1982). Synergistic effect of rifampin, streptomycin, ethionamide, and ethambutol on mycobacterium-intracellulare. Am. Rev. Resp. Dis., 125, 43-48.
33. Hoffner, S. E., Kratz, M., Olssonliljequist, B., Svenson, S. B., and Kallenius, G. (1989). In vitro synergistic activity between ethambutol and fluorinated quinolones against mycobacterium-avium complex. J. Antimicrob. Chemother., 24, 317-324.
34. Horsburgh, C. R. (1991). Current concepts-mycobacterium-avium complex infection in the acquired-immunodeficiency-syndrome. New Engl. J. Med., 324, 1332-1338.
35. Yajko, D. M., Nassos, P. S., Sanders, C. A., and Hadley, W. K. (1991). Effects of antimicrobial agents on survival of mycobacterium-avium complex inside alveolar macrophages obtained from patients with human-immunodeficiency-virus infection. Antimicrob. Agents Chemother., 35, 1621-1625.
36. Kent, R. J., Bakhtiar, M., and Shanson, D. C. (1992). The in vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of mycobacterium-avium-intracellulare. J. Antimicrob. Chemother., 30, 643-650.
37. Manchester. K. (1984). Tuberculosis and leprosy in antiquity. Med. History, 28, 162-73.
38. Rastogi, N. (ed.) (1991). 7th Forum: Structure and function of the cell envelope Res. Microbiol., 142, 419-481.
39. Rastogi, N. (ed.) (1990). 5th Forum: Killing intracellular mycobacteria Res Microbiol., 141, 191-270.
40. Rastogi, N. (ed.) (1993). 9th Forum: Emergence of multiple-drug resistant tuberculosis. Res. Micrbiol., 144, 103-159.
41. Streptomycin treatment of pulmonary tuberculosis: A medical research council investigation (1948). Br. Med. J., II, 769-782.
42. Combined treatment of tuberculosis with streptomycin and PAS (1949). Br. Med. J., II, 1521.
43. British National Formulary (1993). London: Br. Med. Assoc. and Royal Pharm. Soc. GB.
44. Iseman, M. D. (1985). Tailoring a time bomb. Am. Rev. Resp. Dis., 132, 735-736.
45. Iseman, M. D. (1993). Treatment of multi-drug-resistant tuberculosis. New Engl. J. Med., 784.
46. Place, V. A., Peets, E. A., Buyske, D. A., and Little, L. R. (1966). Metabolic and special studies of ethambutol in normal volunteers and tuberculous patients. Annal N.Y. Acad. Sci., 135, 775-795.
47. Place, V. A., Pyle, M. M., and De La Huerga, J. (1969). Ethambutol in tuberculous meningitis. Am. Rev. Resp. Dis., 99, 783-785.
48. Kelly, R. G., Kaleita, E., and Eisner, H. J. (1981). Tissue distribution of ethambutol-C-14 in mice. Am. Rev. Resp. Dis., 123, 689-690.
49. Varughese, A., Brater, D. C., Benet, L. Z., and Lee, C. S. C., (1986). Ethambutol kinetics in patients with impaired renal-function. Am. Rev. Resp. Dis., 134, 34-38.
50. Liss, R. H., Letourneau, R. J., and Schepis, J. P. (1981). Distribution of ethambutol in primate tissues and cells. Am. Rev. Resp. Dis., 123, 529-532.
51. Thomas, J. P. and Durr, F. E. (1983). Ethambutol dose-plasma level correlation studies in guinea-pigs. Am. Rev. Resp. Dis., 127, 352-353.
52. Lee, C. S. E. and Varughese, A. (1984). A disposition kinetics of ethambutol in nephrectomized dogs. J. Pharmaceut. Sci., 73, 787-789.
53. Chen, M. M., Lee, C. S., and Perrin, J. H. (1984). Absorption and disposition of ethambutol in rabbits. J. Pharmaceut. Sci., 73, 1053-1055.
54. Varughese, A., Brater, D. C., Benet, L. Z., and Lee, C. (1984). Pharmacokinetics of ethambutol in renal-failure. J. Clin. Pharmacol., 24, 410.
55. Sokolova, G. B., Ziya, A. V., Abramovich, A. G., Bessarabova, T. N., and Ivleva, A. Y. (1986). Pharmacokinetics of ethambutol in patients with pulmonary tuberculosis. Farmakologiya I Toksikologiya, 49, 40-42.
56. McDougall, J. I. (1991). Lederle Laboratories, Cyanamid GB, Gosport (personal communication).
57. Ohya, K., Shintani, S., and Sano, M. (1980). Determination of ethambutol in plasma using selected ion monitoring. J. Chromatog., 221, 293-299.
58. Holdiness, M. R., Israili, Z. H., and Justice, J. B. (1981). Gas chromatographicmass spectrometric determination of ethambutol in human-plasma. J. Chromatog., 224, 415-422.
59. Billian, J. H., and Diesing, A. C. (1957). J. Org. Chem., 22, 1068.
60. Bernadi, L., Foglio, M., and Temperilli, A. (1974). J. Med. Che., 17, 555.
61. US 3 953 513 (1976). Gruppo Lepetit, Ert 27.4.
62. DE 2 263 715 (1972). Soc. Farma. Italia, Anm. 28. 12.
63. Ye-Sook, K., Jeong-Rok, Y., Man-Ki, P., and Nam-Ho, P. (1981). Determination of the optical isomers of ethambutol (myambutol) and 2-amino-1-butanol by GLC. Arch. Pharm. Res., 4, 1-8.
64. BE-P 862 627 (1978). American Cyanamid, Anm. 4.1.
65. DE 2 547 654 (1975). Basf, Anm. 24.10.
66. US 3 553 257 (1971). American Cyanamid, Ert 5.1.
67. McDougall, J. I. (1994). Lederle Laboratories, Cyanamid GB, Gosport (personal communication).
68. DE 2 446 320 (1974). Denki Kagaku Kogyo, Anm. 27.9.
69. GB 1 471 838 (1975). Nippon Soda, Anm. 26.3.
70. Holdiness, M. R. (1986). Contact-dermatitis to ethambutol. Contact Derm., 15, 96-97.
71. Kerremans, A., Majoor, C. L. H., and Gribnau, F. W. J. (1981). Hypersensitivity to ethambutol. Tubercle, 62, 215-217.
72. Prasad, R. and Mukerji, P. K. (1989). Ethambutol induced thrombocytopaenia. Tubercle, 70, 211-212.
73. Tabak, D., (1988). Determination of ethambutol hydrochloride in air by using fluoropore filter sampling and a derivatisation GC procedure. Am. Indus. Hyg. Assoc. J., 49, 620-623.
74. Shingbal, D. M. and Naik, S. D. (1982). Colorimetric determination of ethambutol hydrochloride. J. Assoc. Off. Analy. Chemists, 65, 899-900.
75. Ng, T. L. (1982). An investigation into the various factors influencing the pharmacopoeial assay of ethambutol hydrochloride tablets. Analyst, 107, 695-700.
76. Hassan, S. S. M. and Shalaby, A. (1992). Determination of ethambutol in pharmaceutical preparations by atomic-absorption spectrometry. Spectrophotom. Potentiom. Mikrochimica Acta, 109, 193-199.
77. Mbay, M. T. and Bosly, J. (1981). Periodate-oxidation of ethambutol. Journal de Pharmacie de Belgique, 36, 253-254.
78. Lacroix, C., Cerutti, F., Nouveau, J., Menager, S., and Lafont, O. (1987). Determination of ethambutol in plasma by liquid-chromatography and ultraviolet spectrophotometric detection. J. Chromatog.-Biomed. Appl., 415, 85-94
79. Causse, J. E., Pasqualini, R., Cypriani, B., Weil, R., Vandervalk, R., Bally, P., Dupuy, A., Couret, I., Benbarek, M., and Descomps, B., (1990). Labelling of ethambutol with TC-99M using a new reduction procedure-pharmacokinetic study in the mouse and rat. Applied radiation and isotopes. Internat. J. Rad. Appl. Intrument., Part A, 41, 493-496.
80. Nilsson, L. E., Ansehn, S., and Hoffner, S. E. (1988). Rapid susceptibility testing of mycobacterium tuberculosis by bioluminescence assay of mycobacterial ATP. Antimicrob. Agents Chemother., 32, 1208-1212.
81. Hoel, T. and Eng, J. (1991). Radiometric and conventional drug susceptibility testing of mycobacterium-tuberculosis. Apmis, 99, 977-980.
82. Brisson-Noel, A. et al. (1991). Diagnosis of tuberculosis by DNA amplification in clinical practise. Lancet, 338, 364-366.
83. Ng, T. L. (1982). A gas-chromatographic mass-spectrometric study of the trimethylsilylation of ethambutol and a tablet assay-method based on the trimethylsilyl derivative. J. Chromatog. Sci., 20, 479-482.
84. Ye-Sook, K., Jeong-Rok, Y., Man-Ki, P., Nam-Ho, P. (1981). Determination of the optical isomers of ethambutol (myambutol) and 2-amino-1-butanol by GLC. Arch. Pharm. Res., 4, 1-8.
85. Lee, C. S. and Benet, L. Z. (1976). GLC determination of ethambutol in plasma and urine of man and monkey. J. Chromatog, 128, 188-192.
86. Bennet, R. M., Manno, J. E., and Manno, B. R. (1974). GC determination of ethambutol. J. Chromatog., 89, 80-83.
87. Lee, C. S. and Bennet, L. Z. (1987). Micro and macro GLC determination of ethambutol in biological fluids. J. Pharm. Sci., 67, 470-473.
88. Bessarabova, T. N., Linberg, L. F., Popov, S. A., and Mirimskii, A. S. (1987). The method of determination of ethambutol in blood serum. Otkrytiya, Izobretaniya, 32, 175.
89. Ohya, K., Shintani, S., and Sano, M. (1980). Determination of ethambutol in plasma using selected ion monitoring. J. Chromatog., 221, 293-299.
90. Lee, C. S. and Wang, L. H. (1980). Improved GLC determination of ethambutol. J. Pharm. Sci., 69, 362-363.
91. Holdiness, M. R., Israili, Z. H., and Justice, J. B. (1981). Gas chromatographicmass spectrometric determination of ethambutol in human-plasma. J. Chromatog., 224, 415-422.
92. Sen, A. K., Bandyopadhyay, A., Podder, G., and Chowdhury, B. (1990). Reversed-phase high-performance liquid-chromatographic determination of ibuprofen and ethambutol in pharmaceutical dosage form. J. Ind. Chem. Soc., 67, 443-444.
93. Blessington, B. and Beiraghi, A. (1990). Study of the stereochemistry of ethambutol using chiral liquid-chromatography and synthesis. J. Chromatog., 522, 195-203.
94. Belov, Y. (1990). Inst. Physiologically Active Subst., Chernogolovka, Moscow, Russia (personal communication).
95. Gubitz, G. (1993). Inst. fur Pharmazeutische Chemie der Karl-Franzens Univ., Graz, Austria (personal communication).
96. Kitigawa, T., Oie, S., and Taniyama, H. (1976). Analysis of d-ethambutol by circular dichroism of its copper chelates. Chem. Pharm. Bull., 24, 3019-3024.
97. Gambertini, G. and Ferioli, V. (1988). Determination of optical purity by HPLC of compounds of pharmaceutical interest. Farmaco Ed. Prat., 43:11, 357-363.
98. Blackwood, J. E, Blower, P. E., Layten, S. W., Lillie, D. H., Lipkus, A. H., Peer, J. P., Qian, C., Staggenborg, L. M., and Watson, C. E. (1991). Chemical abstracts service chemical registry system 13. Enhanced handling of stereochemistry. J. Chem. Inf. Comput. Sci., 31, 205-212.
99. Godfrey, R., Hargreaves, R., and Hitchcock, P. B. (1992). Absolute configuration of (+) ethambutol hydrobromide. Acta. Crystallog., Section C, 48, 79-81.
100. Sorensen, A. M. and Simonsen, O. (1989). (R,S)-2,2′-(1,2-ethanediyldi-imino)-bis(1-butanol)dihydrochloride 45. Acta Cryst., C (cr. str. comm.), 45, 506.
101. Hamalainen, M., Lehtinen, M., and Ahlgren, M. (1985). (S,S)-ethambutol dihydrochloride. Arch. Pharm., 318, 26.
102. Harada, N. and Nakanishi, K. (1983). Circular Dichroic Spectroscopy. London: Oxford Univ. Press.
103. Blessington, B. and Lo, T. W. (1993). A failure of exciton coupled circular dichroism to predict absolute stereochemistry. A preliminary computer modelling explanation. 4th Int. Symposium on Chiral Discrimination, Montreal.
104. Coulson, C. J. (1994). Molecular Mechanisms of Drug Action. London: Taylor and Francis.
105. King, A. and Schwartz, R. (1985). Effects of a chelating drug, ethambutol, on zinc-absorption and tissue distribution in zinc-adequate and zinc-marginal rats. Fed. Proc., 44, 542.
106. Bogden, J. D., Zadzielski, E., Alrabiai, S., and Aviv, A. (1983). Effect of chelating drugs on metabolism of essential metals. 1. Ethambutol. Fed. Proc., 42, 827.
107. King, A. B. and Schwartz, R. (1987). Effects of the antituberculous drug ethambutol on zinc-absorption, turnover and distribution in rats fed diets marginal and adequate in zinc. J. Nutr., 117, 704-708.
108. Bhattacharyya, R. G., Paul, U. K., Chatterjee, A. B., and Bag, S. P. (1990). Interaction of ethambutol with transition-metal ions in solution-formation-constants and stereochemical configurations of the Cu(II), Ni(II), Co(II) and Zn(II) complexes and underlying biological implications. Ind. J. Chem., Sec. A: Inorg. Bio.-Inorg. Phys., 29, 986-995.
109. King, A. and Schwartz, R. (1986). Possible potentiation of ethambutol effects on serum and urine Ca, Mg, and Zn by induction of drug-metabolism. Fed. Proc., 45, 1097.
110. Forbes, M., Kuck, N. A., and Peets, E. A. (1962). Mode of action of ethambutol. J. Bacteriol., 84, 1099-1103.
111. Forbes, M., Kuck, N. A., and Peets, E. A. (1965). Effect of ethambutol on nucleic acid metabolism in mycobacterium smegmatis and its reversal by polyamines and divalent cations. J. Bacteriol., 89, 1299-1305.
112. Poso, H., Paulin, L., and Brander, E. (1983). Specific-inhibition of spermidine synthase from mycobacteria by ethambutol. Lancet, 2, 1418.
113. Paulin, L. G., Brander, E. E., and Poso, H. J. (1985). Specific-inhibition of spermidine synthesis in mycobacteria spp by the dextro isomer of ethambutol. Antimicrob. Agents Chemother., 28, 157-159.
114. Hoffner, S. E., Kratz, M., Olssonliljequist, B., Svenson, S. B., Kallenius, G. (1989). In vitro synergistic activity between ethambutol and fluorinated quinolones against mycobacterium-avium complex. J. Antimicrob. Chemother., 24, 317-324.
115. Rastogi, N., Labrousse, V., and Desousa, J. P. C. (1993). Ethambutol potentiates extracellular and intracellular activities of clarithromycin, sparfloxacin, amikacin, and rifampin against mycobacterium-avium. Current Microbiol., 26, 191-197.
116. Yates, M. D. and Collins, C. H. (1981). Sensitivity of opportunist mycobacteria to rifampicin and ethambutol. Tubercle, 62, 117-121.
117. Sareen, M. and Khuller, G. K. (1990). Cell-wall and membrane-changes associated with ethambutol resistance in mycobacterium-tuberculosis H37RA. Antimicrob. Agents Chemother., 34, 1773-1776.
118. Cheema, S., Asotra, S., and Khuller, G. K. (1985). Ethambutol induced leakage of phospholipids in mycobacterium-smegmatis. IRCS Med. Sci.-Biochem., 13, 843-844.
119. Takayama, K. and Datta, A. K. (1991). Structure-to-function relationship of mycobacterial cell-envelope components. Res. Microbiol., 142, 443-448.
120. Kilburn, J. O. and Takayama, K. (1981). Effects of ethambutol on accumulation and secretion of trehalose mycolates and free mycolic acid in mycobacterium-smegmatis. Antimicrob. Agents Chemother., 20, 401-404.
121. Kilburn, J. O., Takayama, K., Armstrong, E. L., and Greenberg, J. (1981). Effects of ethambutol on phospholipid-metabolism in mycobacterium-smegmatis. Antimicrob. Agents Chemother., 19, 346-348.
122. Cheema, S., Asotra, S., and Khuller, G. K. (1986). Correlation of amino-acid uptake and susceptibility to ethambutol (EMB) with phospholipid-composition of EMB-sensitive and EMB-resistant strains of mycobacterium-smegmatis. Ind. J. Exp. Biol., 24, 705-709.
123. Sareen, M. and Khuller, G. K. (1990). Effect of ethambutol on the phospholipids of ethambutol susceptible and resistant strains of mycobacterium-smegmatis ATCC-607. Ind. J. Biochem. Biophys., 27, 39-42.
124. Cheema, S. and Khuller, G. K. (1985). Phospholipid-composition and ethambutol sensitivity of mycobacterium-smegmatis ATCC-607. Ind. J. Exp. Bio., 23, 511-513.
125. Cheema, S. and Khuller, G. K. (1985). Metabolism of phospholipids in mycobacterium-smegmatis ATCC 607 in the presence of ethambutol. Ind. J. Med. Res., 82, 207-213.
126. Sareen, M. and Khuller, G. K. (1988). Phospholipids of ethambutol-susceptible and resistant strains of mycobacterium-smegmatis. J. Biosci., 13, 243-248.
127. Cheema, S., Asotra, S., and Khuller, G. K. (1987). Effect of exogenous fatty-acids on ethambutol susceptibility of sensitive and resistant mycobacterium-smegmatis ATCC-607. Ind. J. Exp. Biol., 25, 230-232.
128. Silve, G., Valeroguillen, P., Quemard, A., Dupont, M. A., Daffe, M., and Laneelle, G., (1993). Ethambutol inhibition of glucose-metabolism in mycobacteria - a possible target of the drug. Antimicrob. Agents Chemother., 37, 1536-1538.
129. Takayama, K. and Kilburn, J. O. (1989). Inhibition of synthesis of arabinogalactan by ethambutol in mycobacterium-smegmatis. Antimicrob. Agents Chemother., 33, 1493-1499.
130. Sareen, M. and Khuller, G. K. (1990). Cell-wall composition of ethambutol susceptible and resistant strains of mycobacterium-smegmatis ATCC-607. Lett. Appl. Microbiol., 11, 7-10.
131. Hoffner, S. E. and Svenson, S. B. (1991). Studies on the role of the mycobacterial cell-envelope in the multiple-drug resistance of atypical mycobacteria. Res. Microbiol., 142, 448-451.
132. Gigon, S. and Dehaller, R. (1983). Retinal damage caused by ethambutol and serum levels of zinc and vitamin A. Klinische Monatsblatter fur Augenheilkunde, 182, 469-473.
133. Yiannikas, C. and Walsh, J. C. (1982). The use of visual evoked-responses in the detection of subclinical optic neuritis secondary to ethambutol. Neurology, 32, 4.
134. Cremieux, A., Baghdadi, N., Berthelot, P., and Debaert, M. (1983). Antimycobacterial effects of some analogs of ethambutol. Annales de Microbiologie, 2, 177-182.
135. Berthelot, P., Debaert, M., Cremieux, A., and Baghadi, N. (1983). Cyclic analogs of ethambutol active against mycobacteria. Farmaco-Edizione Scientifica, 38, 73-80.
136. Mazumdar, U. K. and Dey, D. C. (1985). Preparation and evaluation of ethambutol derivatives. Ind. J. Pharm. Sci., 47, 179-180.
137. Klyne, W. and Buckingham, J. (1974). Atlas of Stereochemistry. London: Chapman and Hall.
138. Moffat, A. C. (e.d.) (1986). Clarke's Isolation and Identification of Drugs, 2nd ed. London: Pharmaceutical Press.
139. Blessington, B, Beiraghi, A., Lo, T. W., Drake, A., and Jonas, G. (1992). Chiral HPLC-CD studies of the antituberculosis drug (+) ethambutol. Chirality, 4, 227-229.
140. Blessington, B. and Beiraghi, A. (1991). A Method for the quantitative enantioselective HPLC analysis of ethambutol and its stereoisomers. Chirality, 3, 139-144.
141. Deng., L. Y., Mikusova, K., Robuck, K. G., Scherman, M., Brennan, P. J., and McNeil, M. R. (1995). Recognition of multiple effects of ethambutol on metabolism of Mycobacterial cell envelope. Antimicrobial Agents and Chemotherapy., 39(3), 694-701.
142. Mikusova, K., Slayden, R. A., Besra, G. S., and Brennan, P. J. (1995). Biogenesis of the Mycobacterial cell wall and the site of action of ethambutol. Antimicrobial agents and chemotherapy. 39(11), 2484-2489.
143. Brennan, P. J., Colorado State University, College of Veterinary Medicine and biomedical Sciences, Department of Microbiology, Fort Collins, Colorado, Personal communication, Jan 1996.